$30.88
+0.56(1.86%)
Mkt Cap $1.6B
$24.53
$40.22
52-Week Range
At A Glance
1
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases.
2
Revenue is primarily driven by Sale Of Therapies (98.9%) and Collaboration Revenue (1.1%).
3
Most recently: . Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January (2026-01-30).
$1.6B
Market Cap
$376M
Revenue
-$27M
Net Income
Employees493
Fundamentals
How The Business Makes Money
Revenue by Segment
Sale Of Therapies98.9%($1.9B)
Collaboration Revenue1.1%($22M)
Revenue by Geography
US68.9%($653M)
Europe28.7%($272M)
International2.4%($23M)
Activity
What Changed Recently
Company Profile
CIK0001671927
ISINUS45258D1054
CUSIP45258D105
Phone44 12 3543 8600
Address92 Park Drive, Abingdon, OX14 4RY, GB
SEC EDGAR